Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a small molecule Abelson tyrosine kinase inhibitor to treat Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. It has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.
Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a small molecule Abelson tyrosine kinase inhibitor to treat Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. It has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.